LENSAR, Inc (LNSR)

Etorro trading 970x250
LENSAR, Inc (LNSR) Logo

About LENSAR, Inc

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company was incorporated in 2004 and is headquartered in Orlando, Florida. Address: 2800 Discovery Drive, Orlando, FL, United States, 32826

LENSAR, Inc News and around…

Latest news about LENSAR, Inc (LNSR) common stock and company :

We Think LENSAR (NASDAQ:LNSR) Can Afford To Drive Business Growth
02 Oct, 2021 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

LENSAR to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
02 Sep, 2021 FinancialContent

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

LENSAR to Present at the H.C. Wainwright Ophthalmology Virtual Conference
16 Aug, 2021 FinancialContent

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer will present at the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021.

LENSAR Reports Second Quarter 2021 Financial Results and Provides Business Update
05 Aug, 2021 FinancialContent

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2021 and provided an update on key strategic and operational initiatives.

LENSAR to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021
29 Jul, 2021 FinancialContent

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s second quarter 2021 financial results will be released before market open on Thursday, August 5, 2021. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Thursday, August 5, 2021 to discuss the financial results and recent corporate highlights.

LENSAR Announces In-Person Demonstrations of Its Next Generation ALLY™ System and Multiple Data Presentations at the American Society of Cataract and Refractive Surgery (ASCRS) 2021 Annual Meeting
15 Jul, 2021 FinancialContent

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced a total of 12 abstracts highlighting LENSAR’s technology have been accepted for presentation at the 2021 Annual Meeting of the American Society of Cataract and Refractive Surgeons, being held July 23-27, 2021 in Las Vegas, NV.

LENSAR to Present at the Oppenheimer MedTech, Tools, & Diagnostics Summit
24 May, 2021 FinancialContent

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer will present at the Oppenheimer MedTech, Tools, & Diagnostics Summit on May 26, 2021.

LENSAR Reports First Quarter 2021 Financial Results and Provides Business Update
05 May, 2021 FinancialContent

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the first quarter ended March 31, 2021 and provided an update on key strategic and operational initiatives.

LENSAR Inc to Host Earnings Call
05 May, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / May 5, 2021 / LENSAR Inc (NASDAQ:LNSR) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 5, 2021 at 8:30 AM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.

LENSAR to Hold First Quarter 2021 Financial Results Conference Call on Wednesday, May 5, 2021
28 Apr, 2021 FinancialContent

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s first quarter 2021 financial results will be released before market open on Wednesday, May 5, 2021. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Wednesday, May 5, 2021 to discuss the financial results and recent corporate highlights.

We Did The Math VTWO Can Go To $192
25 Mar, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 ETF (VTWO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $192.34 per unit.

LENSAR Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
10 Mar, 2021 FinancialContent

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on key strategic and operational initiatives.

Earnings Scheduled For March 10, 2021
10 Mar, 2021 FinancialContent

Companies Reporting Before The Bell • BioDelivery Sciences Intl (NASDAQ:BDSI) is estimated to report quarterly ...

LENSAR to Hold Fourth Quarter and Full Year 2020 Financial Results and Business Update Conference Call on Wednesday, March 10, 2021
03 Mar, 2021 FinancialContent

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s fourth quarter and full year 2020 financial results will be released before market open on Wednesday, March 10, 2021. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Wednesday, March 10, 2021 to discuss the financial results and recent corporate highlights.

88 Biggest Movers From Yesterday
24 Feb, 2021 FinancialContent

Gainers Solid Biosciences Inc. (NASDAQ: SLDB) shares surged 41.8% to close at $9.74 on above-average session volume. TimkenSteel ...

Is LENSAR Inc. (LNSR) A Smart Long-Term Buy?
16 Feb, 2021 Yahoo! Finance

Merion Road Capital Management, an investment management firm, published its fourth-quarter 2020 Investor Letter for its ‘MRCM Long Short Small Cap’ and ‘MRCM Long Only Large Cap’– a copy of which can be downloaded here. A return of 11.5% was recorded by its Long Short Small Cap fund for the Q4 of 2020, outperforming its […]

LENSAR to Present at Two Upcoming Investor Conferences
08 Feb, 2021 FinancialContent

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer, will present at two upcoming investor conferences:

12 Health Care Stocks Moving In Wednesday's After-Market Session
03 Feb, 2021 FinancialContent

Gainers Assertio Holdings (NASDAQ:ASRT) shares rose 12.23% to $0.78 during Wednesday's after-market session. This security traded ...

LENSAR Expands Board of Directors with the Appointments of Aimee S. Weisner and Elizabeth G. O’Farrell
01 Feb, 2021 FinancialContent

LENSAR, Inc. (Nasdaq:LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced the expansion of its Board of Directors to seven members with the appointments of Aimee S. Weisner and Elizabeth G. O’Farrell, effective February 1, 2021. In addition to serving on the Company’s Board of Directors, Ms. Weisner will join the Company’s Compensation Committee, and Ms. O’Farrell will chair the Company’s Audit Committee.

We Think LENSAR (NASDAQ:LNSR) Needs To Drive Business Growth Carefully
03 Jan, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, although...

LENSAR to Present at the 32nd Annual Piper Sandler Virtual Healthcare Conference
23 Nov, 2020 FinancialContent

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer will present at the 32nd Annual Piper Sandler Virtual Healthcare Conference. Mr. Curtis’ presentation will be available on-demand beginning at 10:00 a.m. Eastern Time, and can be accessed through the Investors section of the Company's website at https://ir.lensar.com on November 23, 2020 at 10 a.m. Eastern Time. The webcast will be available for two weeks after the presentation has been posted.

LENSAR Announces Presentations at American Academy of Ophthalmology Highlighting the Advantages of Streamline IV in Both Cataract and Astigmatism Corrective Surgery
11 Nov, 2020 FinancialContent

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced that three posters and a paper have been accepted for virtual presentations at the Annual Meeting of the American Academy of Ophthalmology (AAO) being held November 13-15, 2020.

LENSAR Reports Third Quarter 2020 Financial Results and Provides Business Update
09 Nov, 2020 FinancialContent

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the third quarter ended September 30, 2020 and provided an update on key strategic and operational initiatives. The distribution of LENSAR common stock to stockholders of PDL BioPharma, Inc. (“PDL”) (Nasdaq: PDLI) took place on October 1, 2020, and LENSAR began trading as an independent public company on October 2, 2020.

LENSAR to Hold Third Quarter 2020 Financial Results and Business Update Conference Call on Monday, November 9, 2020
02 Nov, 2020 FinancialContent

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s third quarter 2020 financial results will be released after market close on Monday, November 9, 2020. LENSAR’s management will host a conference call and webcast at 4:30 p.m. Eastern Time on Monday, November 9th to discuss the financial results and recent corporate highlights.

76 Biggest Movers From Friday
02 Nov, 2020 FinancialContent

Gainers Marine Petroleum Trust (NASDAQ: MARPS) shares climbed 35.4% to close at $3.33 on Friday. Tricida, Inc. (NASDAQ: TCDA) ...

12 Healthcare Stocks Moving In Friday's Intraday Session
30 Oct, 2020 FinancialContent

Gainers BioLine Rx (NASDAQ:BLRX) stock increased by 74.99% to $2.59 during Friday's regular session. Trading volume ...

64 Biggest Movers From Yesterday
09 Oct, 2020 FinancialContent

Gainers AgeX Therapeutics, Inc. (NYSE: AGE) shares climbed 193.8% to close at $2.48 on Thursday following an amended 13D filing ...

LENSAR, Inc (LNSR) is a NASDAQ Common Stock listed in , ,

970x250